Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2003

View Archived Issues

Adenylate cyclase activators discovered at Nippon Kayaku

Merck designs new factor Xa and/or factor VIIa inhibitors

Novel anti-H. pylori agents that act by inhibiting MurI glutamate racemase

Lundbeck describes novel 5-HT1A ligands with 5-HT reuptake/dopamine receptor activity

GSK researchers discover new DPP inhibitors

Purine-based CDK inhibitors newly identified at Cyclacel

New PDE5 inhibitors in early development at Tanabe Seiyaku

Sunesis and Merck & Co. form Alzheimer's research collaboration

DakoCytomation obtains license for cancer diagnostic antibody

PhotoCure submits NDA for Metvix to FDA

Approvable letter issued for Zelapar

Eligard 30 mg receives FDA approval

Encouraging results obtained for Exanta in prevention of stroke in atrial fibrillation

Theseus Imaging enters clinical trial agreement with NCI for Hynic-Annexin V

U.S. centers cleared to join Pharmos's phase III trial of dexanabinol

Valentis updates progress of phase I del-1 trial

Phase III trial results announced for Riquent

HuMax-CD20 kills rituximab-resistant tumor cells in preclinical studies

New preclinical data reported for HuMax-EGFr

Canadian approval for Xigris

Potentially favorable pharmacokinetic and safety profile confirmed for UK-427857

A potential new target for HIV drugs: LEDGF/p75

Pyranodipyrimidine HIV integrase inhibitors with a novel mode of action

Atypical retinoid exerts potent antiproliferative and proapoptotic effects

Broadly crossreactive HIV-neutralizing antibodies available for licensing from NIH

Antidepressant- and anxiolytic-like effects for MCL-0129, a new MC4 receptor antagonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...